Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-08-15
S
Shelley E. Crary
High Impact
Professor, Pediatric Hematology-Oncology
Also affiliated: Children's Medical Center (2007–2013); Arkansas Children's Hospital (2013–2026); Berkeley College (2019); University of Arkansas Medical Center (2018–2024); Erasmus MC (2023); Clinical Research Institute (2011); Cook Children's Medical Center (2008); Southwestern Medical Center (2008–2010); Center for Cancer and Blood Disorders (2007–2013); Duke Medical Center (2011); Pediatrics and Genetics (2017); Southwestern Medical Center (2009–2010); American Society for Clinical Pathology (2019); The University of Texas Southwestern Medical Center (2005–2013); Amsterdam UMC Location Vrije Universiteit Amsterdam (2023); University of California, Berkeley (2019)
Faculty Researcher
20 h-index
99 pubs
2,051 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Dr. Shelley E. Crary is a Professor of Pediatrics in the Division of Pediatric Hematology-Oncology at the University of Arkansas for Medical Sciences (UAMS) and Arkansas Children’s Hospital (ACH). She holds leadership positions as the Medical Director of the Arkansas Center for Bleeding Disorders and Director of Hematology at ACH. Dr. Crary also serves as Co-Director of the UAMS Clinical and Translational Science Pilot Program, focusing on advancing translational research and supporting career development for junior faculty and fellows.
Her research interests include the treatment of hematologic conditions in children, with recent publications addressing gene therapy for Hemophilia B, anticoagulant therapy for venous thromboembolism, and treatment practices for kaposiform hemangioendothelioma and vascular malformations. Dr. Crary also investigates pharmacokinetic properties of sclerotherapy agents and approaches to coagulopathy in patients with vascular anomalies. Her work has contributed to understanding long-term biological effects in sickle cell disease and defining pediatric refractory immune thrombocytopenia (ITP).
Dr. Crary is actively involved in medical education and mentorship, co-directing the UAMS Master’s in Clinical and Translational Sciences Scholarship Program and participating in the American Society of Hematology (ASH) Classical Hematology Mentorship Program. She earned her undergraduate degree from Washington University in St. Louis and her medical degree from Tulane University School of Medicine, followed by residency at Vanderbilt University and a fellowship at UT Southwestern Medical Center, where she also obtained a Master of Science in Clinical Science.
Metrics
- h-index: 20
- Publications: 99
- Citations: 2,051
Selected Publications
-
Bone Mineral Density, Bone Remodeling Biomarkers, and Hemostatic Correlates in Hemophilia and von Willebrand Disease (2026)
-
ReInspire: A Phase 2 Study of Mutant-Selective PI3Kα Inhibitor, RLY-2608, in Adults and Children with PIK3CA-Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (2026)
-
HTRS2025.P1.27 Prevalence Vitamin D deficiency and risk factors for poor bone health in persons with Hemophilia A and B in Arkansas – A retrospective single institution study (2025)
-
Recombinant von willebrand factor for perioperative management of bleeding in pediatric patients with severe von willebrand disease: Interim results from a phase 3 multicenter study and a phase 3b continuation study (2025)
-
Multimodal neuroimaging and neurocognitive assessment in adolescents with and without sickle cell disease (2025)
-
End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children (2025)
-
Knowledge, interest, and willingness of hematologists and oncologists to care for adults with vascular anomalies (2025)
-
Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment (2025)
-
Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease (2025)
-
Pediatric hematology: selected topics (2025)
-
The Functional Characterization of Venous Thromboembolic Disease (FUVID) study: rationale, design, and methods of a prospective, observational, multicenter study to evaluate mechanisms of exercise intolerance and dyspnea following pediatric pulmonary embolism (2024)
-
Hemostasis and thrombosis risks and management in vascular anomalies (2024)
-
Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children (2024)
-
Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes (2024)
-
What is in a name: defining pediatric refractory ITP (2024)
Grants & Funding
As listed on this researcher's institutional profile.
- CUMG UAMS College of Medicine
- GR034186-Crary-HRSA Great Plains Regional Hemophilia Network-UT University of Texas via UAMS ACHRI Flow Through
- Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting UAMS ACHRI Flow Through
Collaboration Network
Top Collaborators
Joana M. Mack
University of Arkansas for Medical Sciences
7 shared publications
In database
- Pharmacokinetics of bleomycin sclerotherapy in patients with vascular malformations
- How we approach coagulopathy with vascular anomalies
- Hypercoagulability Evaluation in Pediatric Kidney Transplant Recipients to Optimize Outcomes
- Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
- How we approach coagulopathy with vascular anomalies.
Showing 5 of 7 shared publications
Taizo A. Nakano
Children's Hospital Colorado (US)
6 shared publications
- Treatment practices and response in kaposiform hemangioendothelioma: A multicenter cohort study
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
Showing 5 of 6 shared publications
Amanda B. Grimes
Children's Cancer Center (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Shipra Kaicker
Cornell University (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Michele P. Lambert
Children's Hospital of Philadelphia (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Kerry Hege
Riley Hospital for Children (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Manpreet Kochhar
Hasbro Children's Hospital (US)
5 shared publications
- What is in a name: defining pediatric refractory ITP
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Divyaswathi Citla Sridhar
University of Arkansas for Medical Sciences
4 shared publications
In database
- Parental Adverse Childhood Experiences and Health Care Use Among Children With Sickle Cell Disease
- Poor School Performance As an Indicator of Severity of Sickle Cell Disease
- A case of bruising and joint hypermobility: The need to consider genetic testing for platelet disorders
- HTRS2025.P1.27 Prevalence Vitamin D deficiency and risk factors for poor bone health in persons with Hemophilia A and B in Arkansas – A retrospective single institution study
Melissa J. Rose
Nationwide Children's Hospital (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Sanjay Shah
Center for Cancer and Blood Disorders (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Michael Briones
Children's Healthcare of Atlanta (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Jeffrey D. Lebensburger
University of Alabama at Birmingham (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Alexis A. Thompson
Children's Hospital of Philadelphia (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Rukhmi Bhat
Lurie Children's Hospital (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Rohith Jesudas
St. Jude Children's Research Hospital (US)
4 shared publications
- A Phase 3 Study of Eltrombopag Vs. Standard First-Line Management for Newly Diagnosed Immune Thrombocytopenia in Children: Trial in Progress Update
- Efficacy Findings in a Phase 3, Randomized Trial of Eltrombopag Vs. Standard First-Line Treatment for Newly Diagnosed Immune Thrombocytopenia in Children
- Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment
- End-of-study results from the ICON3 pines trial, a phase 3, randomized trial of eltrombopag vs. standard first-line treatment for newly diagnosed immune thrombocytopenia in children
Similar Researchers
Based on overlapping research topics
Joana M. Mack
University of Arkansas for Medical Sciences
Vascular Malformations and Hemangiomas
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
KJ Tharappel
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Child and Adolescent Health
Gresham T. Richter
University of Arkansas for Medical Sciences
Vascular Malformations and Hemangiomas
Pharmacological Effects and Toxicity Studies
Child and Adolescent Health
Tonya Balmakund
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Child and Adolescent Health
L Walters
University of Arkansas for Medical Sciences
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies
Medical Research
Kathleen Neville
University of Arkansas for Medical Sciences
Vascular Malformations and Hemangiomas
Metabolism and Genetic Disorders
Pharmacological Effects and Toxicity Studies